CARsgen Therapeutics Holdings Limited (2171.HK)
HKD 14.98
(1.22%)
HKD 14.98
(1.22%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -717.63 Million CNY | 9.61% |
| 2022 | -793.89 Million CNY | -53.29% |
| 2021 | -517.89 Million CNY | -80.97% |
| 2020 | -286.17 Million CNY | -38.65% |
| 2019 | -206.4 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | - CNY | 0.0% |
| 2024 Q1 | - CNY | 0.0% |
| 2023 Q2 | -170.66 Thousand CNY | 0.0% |
| 2023 FY | - CNY | 9.61% |
| 2023 Q3 | -188.15 Thousand CNY | -10.24% |
| 2023 Q1 | -170.66 Thousand CNY | 13.47% |
| 2023 Q4 | -188.15 Thousand CNY | 0.0% |
| 2022 FY | - CNY | -53.29% |
| 2022 Q2 | -177.13 Thousand CNY | 0.0% |
| 2022 Q1 | -177.13 Thousand CNY | -7.17% |
| 2022 Q3 | -197.22 Thousand CNY | -11.34% |
| 2022 Q4 | -197.22 Thousand CNY | 0.0% |
| 2021 Q2 | -110.95 Thousand CNY | 0.0% |
| 2021 Q4 | -165.28 Thousand CNY | 0.0% |
| 2021 Q3 | -165.28 Thousand CNY | -48.97% |
| 2021 Q1 | -110.95 Thousand CNY | -18.84% |
| 2021 FY | - CNY | -80.97% |
| 2020 Q4 | -93.36 Thousand CNY | 0.0% |
| 2020 FY | - CNY | -38.65% |
| 2020 Q2 | -64.83 Thousand CNY | 0.0% |
| 2020 Q1 | -64.83 Thousand CNY | 0.0% |
| 2020 Q3 | -93.36 Thousand CNY | -44.02% |
| 2019 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 91.23 Million HKD | 886.588% |
| CK Life Sciences Int'l., (Holdings) Inc. | 486.79 Million HKD | 247.42% |